Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
06 juin 2023 08h00 HE
|
Vaxart, Inc.
No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2 norovirus vaccine studies over the next 3 months SOUTH SAN FRANCISCO, Calif., June ...
Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
31 mai 2023 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to...
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
04 mai 2023 16h01 HE
|
Vaxart, Inc.
On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH...
Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4
28 avr. 2023 08h00 HE
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
29 mars 2023 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings,...
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
17 mars 2023 08h00 HE
|
Vaxart, Inc.
Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) --...
Vaxart Provides Business Update and Full Year 2022 Financial Results
15 mars 2023 16h01 HE
|
Vaxart, Inc.
Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance...
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
08 mars 2023 16h05 HE
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
14 févr. 2023 08h00 HE
|
Vaxart, Inc.
Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced...
Vaxart Names Phillip Lee as Chief Financial Officer
19 déc. 2022 08h00 HE
|
Vaxart, Inc.
Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart,...